Aura Biosciences Ownership
| AURA Stock | USD 7.42 0.07 0.93% |
Aura |
Aura Stock Ownership Analysis
About 83.0% of the company shares are held by institutions such as insurance companies. The book value of Aura Biosciences was presently reported as 3.51. The company recorded a loss per share of 1.73. Aura Biosciences had not issued any dividends in recent years. Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts. Aura Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 52 people. For more info on Aura Biosciences please contact Elisabet Pinos at 617 500 8864 or go to https://www.aurabiosciences.com.Besides selling stocks to institutional investors, Aura Biosciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Aura Biosciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Aura Biosciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Aura Biosciences Quarterly Liabilities And Stockholders Equity |
|
Aura Biosciences Insider Trades History
Roughly 3.0% of Aura Biosciences are currently held by insiders. Unlike Aura Biosciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Aura Biosciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Aura Biosciences' insider trades
Aura Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Aura Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aura Biosciences backward and forwards among themselves. Aura Biosciences' institutional investor refers to the entity that pools money to purchase Aura Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-12-31 | 687.3 K | Regency Capital Management Inc.\de | 2024-12-31 | 609.4 K | T. Rowe Price Associates, Inc. | 2024-12-31 | 556.9 K | Decheng Capital Llc | 2024-12-31 | 515.6 K | B Group, Inc | 2024-12-31 | 472.6 K | Ensign Peak Advisors Inc | 2024-12-31 | 390.7 K | Northern Trust Corp | 2024-12-31 | 387.3 K | Dimensional Fund Advisors, Inc. | 2024-12-31 | 365.8 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 163 K | Matrix Capital Management Company, Llc | 2024-12-31 | 6.9 M | Adage Capital Partners Gp Llc | 2024-12-31 | 4.9 M |
Aura Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aura Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aura Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aura Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aura Biosciences Outstanding Bonds
Aura Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Aura Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Aura bonds can be classified according to their maturity, which is the date when Aura Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Aura Biosciences Corporate Filings
F4 | 18th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
| 3rd of January 2025 Other Reports | ViewVerify | |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Aura Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aura Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aura Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aura Biosciences Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aura Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Aura Stock refer to our How to Trade Aura Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aura Biosciences. If investors know Aura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aura Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Aura Biosciences is measured differently than its book value, which is the value of Aura that is recorded on the company's balance sheet. Investors also form their own opinion of Aura Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Aura Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aura Biosciences' market value can be influenced by many factors that don't directly affect Aura Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aura Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aura Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aura Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.